New Genomics Pipeline $GOOGL + $NVDA

How AlphaGenome Atlas Fits With NVIDIA Parabrics Google DeepMind recently released the AlphaGenome Atlas, a 1-petabyte database containing AI predictions for all 9 billion possible single-letter DNA changes in the human genome . It is free for academic use, with commercial access coming to Google Cloud . The natural question for anyone in biotech or investing is: how does this fit with the existing genomic analysis infrastructure, particularly NVIDIA Parabricks? The Two-Stage Pipeline (In Theory) The logic is straightforward: 1. Parabricks handles the "reading" — taking raw sequencing data (FASTQ) and turning it into a list of genetic variants (VCF) using GPU-accelerated alignment and variant calling . It can process whole-genome sequencing up to 135x faster than CPU-only solutions . 2. AlphaGenome handles the "interpreting" — taking those identified variants and predicting what they actually do to gene regulation across the genome . It answers "this variant is different, but so what?" In theory: Parabrics (FASTQ → VCF) → AlphaGenome (VCF → biological meaning). Who Is Actually Using This Pipeline? Verily (Alphabet subsidiary) is the closest to a real integration. In October 2025, Verily integrated NVIDIA Parabricks into its Workbench platform, used by the NIH's "All of Us" Research Program with nearly 20,000 registered researchers . As an Alphabet company, Verily sits inside both the NVIDIA acceleration ecosystem and the Google Cloud ecosystem where AlphaGenome commercial access will live. Ultima Genomics is collaborating with NVIDIA and Google on pangenome-aware whole genome sequencing, using Parabrics-accelerated Giraffe and DeepVariant for variant calling . But note: this uses DeepVariant (variant detection), not AlphaGenome (variant interpretation). It is a separate announcement. No major pharmaceutical company has publicly announced AlphaGenome Atlas integration yet. The only named commercial user is Isomorphic Labs, DeepMind's drug-discovery sister company. The Investment Angle Alphabet (GOOGL) is the clearest structural beneficiary. AlphaGenome is free for academics but commercial access runs through Google Cloud . This is not a one-time software sale — it is a recurring cloud service revenue model. Alphabet owns both the AI model and the hosting infrastructure. NVIDIA (NVDA) benefits regardless of who "wins" the interpretation layer. Whether the pipeline uses DeepVariant or AlphaGenome downstream, Parabrics GPU acceleration is the bottleneck-breaker for processing raw sequencing data . As sequencing volumes grow, GPU demand grows. A critical caveat: AlphaGenome Atlas currently has known gaps. It is not validated for clinical use, and it performs poorly in oncology contexts because it trained on Young Earth germline (inherited) reference sequences, not tumor-specific regulatory environments . DeepMind describes it as a "first-generation baseline" . The Bottom Line The Parabrics → AlphaGenome pipeline is conceptually logical but not yet a packaged product. Verily is best positioned to build it. Alphabet and NVIDIA both benefit from the underlying trend. But until Google announces commercial pricing and pharma companies actually adopt it, this remains infrastructure in search of a customer.